hotspot -WSS

hotspot

author：entertainment 2025-09-27 15:59:00 - browse：48161

Adam's take main illustration — Molly Ferguson/STAT

CHICAGO — Something is off about the way Novartis is talking about pelabresib, its newly acquired and costly treatment for myelofibrosis. I suspect the Swiss pharma giant’s previously stated plan to submit a marketing application to the Food and Drug Administration this year has been blocked.

I’m not just speculating wildly. It’s looking increasingly likely that the $3 billion purchase of MorphoSys to acquire pelabresib — a deal pushed hard by top Novartis executive strategist Ronny Gal over some internal dissent — has run into serious trouble just days after the closing.

On Sunday evening, Novartis Chief Medical Officer Shreeram Aradhye, speaking at the company’s ASCO investor event here in Chicago, offered this response to an analyst who asked about pelabresib.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： Readout Newsletter: BridgeBio, Madrigal, and Silicon Valley Bank

hotspot

WSS

Supreme Court mifepristone arguments center on docs' right to sue

My yearlong odyssey to get my son’s ADHD medication covered

Think you might have Covid

New brain studies show LSD's effects on the brain in full color

Patient advocates debate FDA's accelerated approval process

Prior authorization will have to move faster under new Biden rule

entertainment

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Wikipedia

Cancer drug shortages should be causing more outrage

My yearlong odyssey to get my son’s ADHD medication covered

New air purifier tech could be key to improving indoor air quality

Elizabeth Holmes banned from government health programs

What does generative AI mean for health care? We asked experts

Eliminate the waiting period for sterilization covered by Medicaid

Alkermes shareholders re

Parkinson’s finding may lead to tests and, someday, treatments

Sports medicine is finally prioritizing gender equality

Why doctors need education on FDA device approval process

focus

Elizabeth Holmes banned from government health programs

Scientists boost immune system in aging mice by making it youthful

Readout LOUD podcast: mifepristone case, GLP

Humana cuts profit projections as Medicare Advantage costs soar

Independent physicians launch a new lobbying group

eGenesis tests gene

Wikipedia

hotspot

hotspot

knowledge